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Objectives: It is well known that familial hypercholesterolemia (FH) is a common inherited disorder that
can markedly elevate the level of plasma LDL cholesterol. However, little data exists regarding the clinical
impact of the plasma triglyceride (TG)-rich lipoprotein fraction, including VLDL and IDL, in FH. Thus, we
assessed the hypothesis that the mutations in the LDL receptor modulate lipoprotein metabolism other
than the LDL fraction.
Design and methods: We investigated plasma lipoprotein with a one-step ultracentrifugation method for
146 controls (mean age¼61.4717.1 yr, mean LDL cholesterol¼92.7761.2 mg/dl), 213 heterozygous
mutation-determined FH subjects (mean age¼46.0718.0 yr, mean LDL cholesterol¼225.1761.2 mg/dl),
and 16 homozygous/compound heterozygous mutation-determined FH subjects (mean age¼26.97
17.1 yr, mean LDL cholesterol¼428.6786.1 mg/dl). In addition, we evaluated cholesterol/TG ratio in each
lipoprotein fraction separated by ultracentrifugation.
Results: In addition to total cholesterol and LDL cholesterol levels, VLDL cholesterol (19.5710.4,
25.2719.3, 29.5721.4 mg/dl, respectively) and IDL cholesterol (8.373.7, 16.8711.5, 40.0737.3 mg/dl,
respectively) exhibited a tri-model distribution according to their status in LDL receptor mutation(s).
Moreover, the ratios of cholesterol/TG of each lipoprotein fraction increased signiﬁcantly in heterozygous
FH and homozygous/compound heterozygous FH groups, compared with that of controls, suggesting that
the abnormality in LDL receptor modulates the quality as well as the quantity of each lipoprotein fraction.
Conclusions: Our results indicate that cholesterol in TG-rich lipoproteins, including VLDL and IDL, are
signiﬁcantly higher in FH subjects, revealing a tri-modal distribution according to the number of LDL
receptor mutations.
& 2015 Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Familial hypercholesterolemia (FH) is the most common and most severe monogenic hypercholesterolemia characterized by excess
deposition of cholesterol in tissues leading to tendon xanthomas and premature coronary artery disease [1–3]. Patients with FH have
mutant allele(s) of either of three FH-associated genes (FH genes), namely LDL receptor, apolipoprotein B-100 and proprotein convertase
subtilisin/kexin 9 (PCSK9) genes [2], among which, LDL receptor is the leading cause of this disorder. Individuals with two mutations in the
LDL receptor gene (homozygous FH) display extremely severe hyper-LDL-cholesterolemia, usually over 400 mg/dl, and develop cutaneous
xanthomas, coronary artery disease, and aortic valve stenosis in childhood [1,2]. If the LDL-cholesterol level is not effectively treated,
homozygous FH die prematurely from an acute coronary event or heart failure [4]. The frequency of heterozygous FH in the general
population has been estimated at about 1 in 500 almost all over the world. Recent advances in genetic analysis has enabled the accuracy of
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diagnosis of heterozygous FH and revealed a much higher frequency of FH in certain populations, such as the Afrikaners, Christian
Lebanese, Finns, and French–Canadians due to a founder gene effect [1].
Triglyceride (TG)-rich lipoprotein, such as VLDL and IDL, are associated with coronary artery disease [5,6]. However, little data exists
regarding the impact of LDL receptor mutations on the metabolism of TG-rich lipoprotein in FH, which could be an additive risk factor for
the development of coronary atherosclerosis. Here, we investigated whether the mutations in the LDL receptor modulate lipoprotein
metabolism other than the LDL fraction using a one-step ultracentrifugation method.
2. Materials and methods
2.1. Study subjects
We investigated plasma lipoprotein by an ultracentrifugation method for 146 controls, 213 heterozygous mutation-determined FH
subjects, and 16 homozygous/compound heterozygous mutation-determined FH subjects. All of the FH subjects have (a) mutant allele
(s) in LDL receptor gene. The characteristics of the study subjects are listed in Table 1.
2.2. Genetic analyses
Genomic DNA was isolated from peripheral blood white blood cells using Genomic DNA Puriﬁcation Kit (Gentra Systems, Minneapolis,
MN) and was used for PCR. The genotypes of all the participants in this study were determined as previously described [7–10]. Genetic
analyses were approved by the Ethics Committee of Kanazawa University and carried out in accordance with the Declaration of Helsinki
(2008) of the World Medical Association. All procedures followed were in accordance with the ethical standards of the responsible
committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. Informed
consents were obtained from all subjects.
2.3. Biochemical analyses
Fasting blood samples were drawn for assays either before the lipid-lowering treatment or after discontinuation of medication for at
least 4 weeks. Blood samples were stored at 4 1C immediately in the pharmaceutical refrigerators (MPR-721, Panasonic healthcare, Tokyo,
Japan) until the process to obtain serum and plasma for within an hour. Serum concentrations of total cholesterol (TC), TG, and HDL
cholesterol (HDL-C) were determined enzymatically (Qualigents, Sekisui Medical, Tokyo, Japan) using automated instrumentation
(LABOSPECT 008, Hitachi High-Technologies, Tokyo, Japan) based on the assays previously described [11–13]. LDL-C concentrations were
derived using the Friedewald formula [14]. Plasma were processed to ultracentrifugation immediately after the acquisition.
2.4. Ultracentrifugation analyses
We used a one-step ultracentrifugation method as described in Fig. 1 [15–17]. Plasma (600 μL) was divided into three different tubes
(each containing 200 μL), then NaBr solutions with different speciﬁc gravity (d¼1.006, 1.032, and 1.120) were added. The least dense
solution (d¼1.006) was overlayed with the plasma, and the other two solutions (d¼1.032, and 1.120) were mixed with plasma, adjusting
the gravities to d¼1.019, and 1.063, respectively. Subsequently, the same three tubes were ultracentrifuged at 42,000 rpm, for 12 h at 10 1C
in a Beckman 42 Ti rotor. The top 200 μL containing VLDL (do1.006 g/ml), and the bottom 200 μL containing IDL, LDL, and HDL were
extracted separately in the tube with the least dense solution. Similarly, the top 200 μL containing VLDL and IDL (do1.019 g/ml), and the
bottom 200 μL containing LDL and HDL were extracted separately in the tube with the higher density solution. Finally, the top 200 μL
containing VLDL, IDL, and LDL (do1.063 g/ml), and the bottom 200 μL containing HDL were extracted separately in the tube with the
highest density solution. Cholesterol ester (calculated as total cholesterol minus free cholesterol), and TG were analyzed in each
ultracentrifugally separated lipoprotein as described above.
Table 1
Characteristics of the study subjects.
Variable Controls (n¼146) Heterozygous FH (n¼213) Homozygous/compound heterozygous FH (n¼16)
Age (yr) 61.4717.1 46.0718.0n 26.9717.1nn
Men (%) 91 (62%) 87 (41%) 11 (69%)
BMI (kg/m2) 25.873.8 23.472.9 25.474.4
TC (mg/dl) 193721 321766nn 7017160nn
VLDL-C (mg/dl) 19.5710.4 25.2719.3n 29.5721.4nn
IDL-C (mg/dl) 8.373.7 16.8711.5nn 40.0737.3nn
LDL-C (mg/dl) 93761 225761nn 429786nn
HDL-C (mg/dl) 57717 53725 39710n
TG (mg/dl) 88712 142773nn 170786nn
VLDL-TG (mg/dl) 42.0724.0 56.2755.3n 43.9728.6
IDL-TG (mg/dl) 7.073.2 11.577.2n 13.8710.4nn
LDL-TG (mg/dl) 19.076.3 35.0716.4nn 68.2729.5nn
HDL-TG (mg/dl) 12.176.3 12.875.4 12.077.2
FH: familial hypercholesterolemia, BMI: body mass index, TC: total cholesterol, VLDL-C: VLDL cholesterol, IDL-C: IDL cholesterol, LDL-C: LDL cholesterol, HDL-C: HDL
cholesterol, TG: triglyceride,VLDL-TG: VLDL triglyceride, IDL-TG: IDL triglyceride, LDL-TG: LDL triglyceride, and HDL-TG: HDL triglyceride.
n po0.05.
nn po0.0001 vs controls.
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2.5. Statistical analysis
Continuous variables with a normal distribution were shown as mean (7SD), and were compared using unpaired Student t-tests, and
those with non-normal distribution were compared using Mann–Whitney U test. Categorical variables were expressed as percentages, and
were compared using chi-square test. Analyses were conducted using R statistical software [18]. We determined data were normally
distributed using Jarque–Bera test through R package (tseries). All p values o0.05 were considered statistically signiﬁcant.
3. Results
3.1. Baseline characteristics of study subjects
Baseline characteristics, including lipid proﬁles determined enzymatically in 146 controls (mean age¼61.4717.1 yr, mean LDL-
C¼92.7761.2 mg/dl), 213 heterozygous mutation-determined FH subjects (mean age¼46.0718.0 yr, mean LDL-C¼225.1761.2 mg/dl),
and 16 homozygous/compound heterozygous mutation-determined FH subjects (mean age¼26.9717.1 yr, mean LDL-C¼428.6786.1 mg/dl),
are listed in Table 1. Tables 2 and 3 provide the genetic backgrounds of the heterozygous FH and homozygous/compound heterozygous FH
subjects, respectively.
Ultracentrifugation
(Lp-42 Ti Rotor, 42,000 rpm, 222,000 G, 12 hours)
solution 200 μL (d=1.006) solution 200 μL (d=1.032) solution 200 μL (d=1.120)
VLDL
IDL+LDL+HDL
VLDL+IDL
LDL+HDL
VLDL+IDL+LDL
HDL
plasma 600 μL
plasma 200 μL plasma 200 μL plasma 200 μL
overlay mixing (d=1.019) mixing (d=1.063)
Fig. 1. Schema of one-step ultracentrifugation analysis for lipoprotein. Light blue liquid indicates solution. Orange liquid indicates plasma. Light orange indicates the top
200 μL after ultracentrifugation. Brown indicates the bottom 200 μL after ultracentrifugation.
Table 2
Genetic background of the study subjects with heterozygous FH.
Nucleotide change Mutation type Effect on protein Number of patients
c.68-?_313þ?del Large deletion Truncated protein 15
c.191-?_940þ?dup Large duplication Truncated protein 6
c.344G4A Missense Arg-His 1
c.413C4G Nonsense Ser-stop 3
c.539G4A Nonsense Trp-stop 1
c.662_665dupACTG Duplication Frameshift/stop 1
c.682G4A Missense Glu-Lys 2
c.797A4G Missense Asp-Gly 1
c.901G4T Missense Asp-Tyr 1
c.1012T4A Missense Cys-Ser 2
c.1285G4A Missense Val-Met 1
c.1297G4C Missense Asp-His 2
c.137G4A Missense Cys-Tyr 1
c.1432G4A Missense Gly-Ala 1
c.1474G4A Missense Asp-Asn 1
c.1567G4A Missense Val-Met 1
c.1689dupC Duplication Frameshift/stop 1
c.1702C4G Missense Leu-Val 1
c.1778dupG Duplication Frameshift/stop 1
c.1845þ2T4C Splicing exon13 skip 1
c.1871_1873delTCA Deletion 603 Ile deletion 5
c.2054C4T Missense Pro-Leu 32
c.2140þ1G4T Splicing exon15 skip 3
c.2141-?_2311þ?del Large deletion Truncated protein 7
c.2312-3C4A Splicing exon16 skip 25
c.2431A4T Nonsense Lys-stop 97
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3.2. Lipoprotein subfractions separated by ultracentrifugation and ratios of cholesterol/triglyceride in each lipoprotein fractions
In addition to TC and LDL-C levels, cholesterol levels in TG-rich lipoprotein fractions separated by ultracentrifugation also exhibited
tri-modal distributions according to the mutation status in the LDL receptor (VLDL-C levels were 19.5710.4, 25.2719.3, and 29.57
21.4 mg/dl, respectively; IDL-C levels were 8.373.7, 16.8711.5, and 40.0737.3 mg/dl, respectively; Fig. 2).
Moreover, the ratios of cholesterol/TG in each lipoprotein fraction also exhibited similar tri-modal distributions, suggesting that the
status of mutation(s) in the LDL receptor modulates not only metabolism in the LDL fraction, but also in VLDL and IDL fractions (Fig. 3). We
also investigated the correlations between lipoprotein fractions separated by ultracentrifugation and enzymatically determined lipid
proﬁles (Supplemental Tables 1–3, and Supplemental Figs. 1–12). As expected, enzymatically determined TG levels exhibited good
correlations with levels of VLDL-TG and IDL-TG.
4. Discussion
Using a FH cohort of 213 heterozygous and 16 homozygous/compound heterozygous mutation-determined subjects, we sought to
evaluate if cholesterol in TG-rich lipoprotein levels separated by ultracentrifugation are higher in FH subjects. We found that cholesterol in
those TG-rich lipoproteins, including VLDL and IDL, were signiﬁcantly higher in FH subjects, revealing a tri-modal distribution according to
the number of mutations. In addition to the total amount, the ratio of cholesterol/TG in each lipoprotein fraction was also signiﬁcantly
higher in FH subjects, showing a tri-modal distribution.
Patients with heterozygous FH, which is estimated to be at least 20 million worldwide exhibit premature coronary atherosclerosis, thus
their risk of future coronary events needs to be assessed [19,20]. There are a number of biomarkers for the prediction of coronary events,
such as age, sex, LDL-C level and cholesterol in TG-rich lipoprotein levels [21–23]. In this study, we clearly demonstrated that cholesterol in
TG-rich lipoprotein levels separated by ultracentrifugation were signiﬁcantly and quantitatively higher in FH subjects. In addition, our
study has a strength in the determination of mutation status in LDL receptor, providing a comparison of TG-rich lipoproteins between
patients with FH exhibiting single LDL receptor mutation and those with double mutations.
Possible mechanisms of those increased cholesterol in TG-rich lipoproteins could be (1) increased production of VLDL, as demonstrated
in several kinetic studies in vivo [24], or (2) disturbed clearance of TG-rich lipoproteins via a dysfunctional LDL receptor [25]. In accordance
with these hypotheses, we have previously demonstrated that the clearance of post-prandial remnant lipoproteins in FH was also
disturbed [26]. In addition, lipoprotein lipase and hepatic lipase which are expected to remove TG and therefore enrich cholesterol content
in TG-rich lipoproteins have been shown to be elevated in FH subjects and in Watanabe heritable hyperlipidaemic rabbits [27,28]. Such
elevation of lipase should contribute to the modulation of cholesterol content in FH observed in this study. Furthermore, the clearance of
TG-rich lipoproteins seem to be preserved in autosomal recessive hypercholesterolemia which is caused by loss of function mutation in
Table 3
Genetic background of the study subjects with homozygous/compound heterozygous FH.
Nucleotide changes Mutation types Effect on proteins Number of patients
c.901G4T/c.901G4T Missense/missense Asp-Tyr/Asp-Tyr 1
c.2054C4T/c.2431A4T Missense/nonsense Pro-Leu/Lys-stop 2
c.68-?_313þ?del/c.68-?_313þ?del Large deletion/large deletion Truncated protein/Truncated protein 1
c.1246C4T/c.1246C4T Missense/missense Arg-Trp/Arg-Trp 1
c.796G4A/c.796G4A Missense/missense Asp-Asn/Asp-Asn 1
c.1285G4A/c.418G4A Missense/missense Val-Met/Glu-Lys 1
c.1502C4T/c.241dupC Missense/missense Ala-Val/Arg-Cys 1
c.1845þ2T4C/c.1845þ2T4C Splicing/splicing exon13 skip/exon13 skip 2
c.2201_2202delCA/c.2201_2202delCA Nonsense/nonsense Gln-stop/Gln-stop 1
c.661G4A/c.1845þ2T4C Missense/splicing Asp-Asn/exon13 skip 1
c.1012T4A/c.68-?_313þ?del Missense/large deletion Cys-Ser/Truncated protein 2
c.796G4A/c.361T4G Missense/missense Asp-Asn/Cys-Gly 1
c.1567G4A/c.1567G4A Missense/missense Val-Met/Val-Met 1
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Fig. 2. Lipoprotein subfractions determined by ultracentrifugation. White bars indicate controls. Gray bars indicate heterozygous FH. Black bars indicate homozygous FH. TC:
total cholesterol, VLDL: very low-density lipoprotein, IDL: intermediate-density lipoprotein, LDL: low-density lipoprotein, c: controls; he: heterozygous FH; ho: homozygous
or compound heterozygous FH. *po0.05, **po0.0001 vs controls.
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LDL receptor adapter protein 1 gene, contributing to milder phenotype than FH with LDL receptor mutation [29]. This ﬁnding suggests that
TG-rich lipoprotein metabolism is ligand-sensitive. In addition, LDL receptor can transfer such TG-rich lipoproteins to an additional
receptor for uptake by the liver when its internalization is impaired. These pathways are not always via LDL receptor, LDL receptor related
protein and heparan sulfate proteoglycan [30]. Recent Mendelian randomization trials suggested that TG level was the cause of coronary
artery disease, independent of LDL cholesterol [31–34]. Thus, activating such pathway(s) could be one of the desirable therapies for
patients with FH.
Our study has several limitations. This study was an analysis of data from a single center with a relatively small sample size, thus our
results need to be validated through multi-center studies. There were signiﬁcant differences between the subjects' ages in the three
groups (controls, heterozygous FH, and homozygous/compound heterozygous FH), which could affect the results. The controls groups
exhibiting high TC level without mutations in LDL receptor could provide the evidence to support our results were speciﬁc to FH.
In conclusion, our results indicate that cholesterol in TG-rich lipoproteins, including VLDL and IDL, are signiﬁcantly higher in FH
subjects, revealing a tri-modal distribution according to the number of LDL receptor mutations.
Funding sources
This work was supported by a scientiﬁc research grant from the Ministry of Education, Science, and Culture of Japan (No. 26893094).
Conﬂict of interest
Hayato Tada has received research grants from the Banyu Life Science Foundation International, SENSHIN Medical Research Foundation,
and The Uehara Memorial Foundation. Masa-aki Kawashiri has received payments for lectures from Shionogi & Co., Ltd., Daiichi-Sankyo
Co., Ltd., Astellas Pharma Inc., AstraZeneca K.K., Kissei Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Kyowa Hakko Kirin, Co., Ltd. Atsushi
Nohara and Horoshi Mabuchi have received research grants fromMSD K.K., Sanoﬁ K.K., Shionogi & Co., Ltd., Kowa Co., Ltd., Astellas Pharma
Inc., AstraZeneca K.K., Keiai-Kai Medical Corp., and Biopharm of Japan Co. Akihiro Inazu has no ﬁnancial or other relations that could lead
to a conﬂict of interest. Masakazu Yamagishi has received research grants from MSD K.K., Astellas Pharma Inc., Daiichi-Sankyo Co., Ltd.,
Otsuka Pharmaceutical Co., Ltd., and he has received payments for lectures from Astellas Pharma Inc., Daiichi-Sankyo Co., Ltd., Shionogi &
Co., Ltd., Kowa Co., Ltd.
Acknowledgments
None declared.
Appendix A. Supporting information
Supplementary data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.plabm.2015.03.001.
References
[1] Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: 8th ed.. Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of
inherited disease, vol. 2. New York: McGraw-Hill; 2001. p. 2863–913.
[2] Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Pract Cardiovasc Med 2007;4:214–25.
[3] Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 2003;111:1795–803.
[4] Mabuchi H, Koizumi J, Shimizu M, Takeda R. Development of coronary heart disease in familial hypercholesterolemia. Circulation 1989;79:225–32.
[5] Mahley RW. Atherogenic lipoproteins and coronary artery disease: concepts derived from recent advances in cellular and molecular biology. Circulation 1985;72:943–8.
[6] Krauss RM. Atherogenicity of TG-rich lipoproteins. Am J Cardiol 1998;81:13B–7B.
[7] Mabuchi H, Nohara A, Noguchi T, Kobayashi J, Kawashiri MA, Tada H, et al. Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the
Hokuriku district of Japan. Atherosclerosis 2011;214:404–7.
0
1.0
0.5
0
2.0
1.0
VLDL (C/TG ratio) IDL (C/TG ratio) LDL (C/TG ratio)
0
8.0
4.0
c he ho c he ho c he ho
**
**
**
**
**
**
0
5.0
2.5
HDL (C/TG ratio)
c he ho
***
Fig. 3. Cholesterol/triglyceride ratio in each lipoprotein subfractions. White bars indicate controls. Gray bars indicate heterozygous FH. Black bars indicate homozygous
FH. VLDL: very low-density lipoprotein, IDL: intermediate-density lipoprotein, LDL: low-density lipoprotein, HDL: high-density lipoprotein, C: cholesterol; TG: triglyceride,
c: controls; he: heterozygous FH; ho: homozygous or compound heterozygous FH. *po0.05, **po0.0001 vs controls.
H. Tada et al. / Practical Laboratory Medicine 1 (2015) 22–2726
[8] Noguchi T, Katsuda S, Kawashiri MA, Tada H, Nohara A, Inazu A, et al. The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolemia by
increasing PCSK9 function and concentration in the circulation. Atherosclerosis 2010;210:166–72.
[9] Mabuchi H, Nohara A, Noguchi T, Kobayashi J, Kawashiri MA, Inoue T, et al. Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by
proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation. Atherosclerosis 2014;236:54–61.
[10] Tada H, Kawashiri MA, Ikewaki K, Terao Y, Noguchi T, Nakanishi C, et al. Altered metabolism of low-density lipoprotein and very-low-density lipoprotein remnant in
autosomal recessive hypercholesterolemia: results from stable isotope kinetic study in vivo. Circ Cardiovasc Genet 2012;5:35–41.
[11] Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470–5.
[12] Sugiura M, Oikawa T, Hirano K, Maeda H, Yoshimura H, Sugiyama M, et al. A simple colorimetric method for determination of serum triglycerides with lipoprotein
lipase and glycerol dehydrogenase. Clin Chim Acta 1977;81:125–30.
[13] Finley PR, Schifman RB, Williams RJ, Lichti DA. Cholesterol in high-density lipoprotein: use of Mg2þ/dextran sulfate in its enzymic measurement. Clin Chem
1978;24:931–3.
[14] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
Clin Chem 1972;18:499–502.
[15] Hata Y, Ueno T. Ultracentrifugal isolation of LDL and HDL in serum by using Lp-42 Ti Rotor. Rinsho Byori 1981;29:717–22 [in Japanese].
[16] Hata Y, Ueno T, Ogishima K. Fractionation of serum lipoproteins into VLDL, LDL, HDL, HDL2, and HDL3 by 1-step ultracentrifugation. Rinsho Byori 1983;31:634–40 [in
Japanese].
[17] Brousseau T, Clavey V, Bard JM, Fruchart JC. Sequential ultracentrifugation micromethod for separation of serum lipoproteins and assays of lipids, apolipoproteins, and
lipoprotein particles. Clin Chem 1993;39:960–4.
[18] R Core Team R. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2012.
[19] Kawashiri MA, Hayashi K, Konno T, Fujino N, Ino H, Yamagishi M. Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects. Heart Vessels
2014;29:129–41.
[20] Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH
Foundation. Int J Cardiol 2014;171:309–25.
[21] Sugisawa T, Okamura T, Makino H, Watanabe M, Kishimoto I, Miyamoto Y, et al. Deﬁning patients at extremely high risk for coronary artery disease in heterozygous
familial hypercholesterolemia. J Atheroscler Thromb 2012;19:369–75.
[22] Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, et al. Familial hypercholesterolemia. J Atheroscler Thromb 2014;21:6–10.
[23] Graham G, Blaha MJ, Budoff MJ, Rivera JJ, Agatston A, Raggi P, et al. Impact of coronary artery calciﬁcation on all-cause mortality in individuals with and without
hypertension. Atherosclerosis 2012;225:432–7.
[24] Millar JS, Maugeais C, Ikewaki K, Kolansky DM, Barrett PH, Budreck EC, et al. Complete deﬁciency of the low-density lipoprotein receptor is associated with increased
apolipoprotein B-100 production. Arterioscler Thromb Vasc Biol 2005;25:560–5.
[25] James RW, Martin B, Pometta D, Fruchart JC, Duriez P, Puchois P, et al. Apolipoprotein B metabolism in homozygous familial hypercholesterolemia. J Lipid Res
1989;30:159–69.
[26] Tada H, Kawashiri MA, Tanaka A, Nakano T, Nakajima K, Inoue T, et al. Post-prandial remnant lipoprotein metabolism in autosomal recessive hypercholesterolaemia.
Eur J Clin Invest 2012;42:1094–9.
[27] Beauchamp MC, Letendre E, Renier G. Macrophage lipoprotein lipase expression is increased in patients with heterozygous familial hypercholesterolemia. J Lipid Res
2002;43:215–22.
[28] Demacker PN, Mol MJ, Stalenhoef AF. Increased hepatic lipase activity and increased direct removal of very-low-density lipoprotein remnants in Watanabe heritable
hyperlipidaemic (WHHL) rabbits treated with ethinyl oestradiol. Biochem J 1990;272:647–51.
[29] Tada H, Kawashiri MA, Nohara A, Inazu A, Kobayashi J, Mabuchi H, et al. Autosomal Recessive Hypercholesterolemia: a mild phenotype of familial hypercholester-
olemia: insight from the kinetic study using stable isotope and animal studies. J Atheroscler Thromb 2015;22:1–9.
[30] Mahley RW, Huang Y. Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing. J Clin Invest 2007;117:94–8.
[31] Varbo A, Benn M, Tybjærg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll
Cardiol 2013;61:427–36.
[32] Jørgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjærg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant
cholesterol as causal risk factors for myocardial infarction. Eur Heart J 2013;34:1826–33.
[33] Varbo A, Benn M, Tybjærg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inﬂammation and ischemic heart disease, whereas elevated
low-density lipoprotein cholesterol causes ischemic heart disease without inﬂammation. Circulation 2013;128:1298–309.
[34] Thomsen M, Varbo A, Tybjærg-Hansen A, Nordestgaard BG. Low nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study. Clin Chem
2014;60:737–46.
H. Tada et al. / Practical Laboratory Medicine 1 (2015) 22–27 27
